1
|
Negishi T, Kuroiwa K, Hori Y, Tomoda T, Uchino H, Tokuda N, Furubayashi N, Nagase K, Iwai H, Nakamura M. Predictive factors of late biochemical recurrence after radical prostatectomy. Jpn J Clin Oncol 2017; 47:233-238. [PMID: 27940489 DOI: 10.1093/jjco/hyw181] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Accepted: 11/23/2016] [Indexed: 12/29/2022] Open
Abstract
Objective To assess the characteristics of biochemical recurrence in the late period (>5 years after radical prostatectomy) and the differences in the predictors of biochemical recurrence in different periods, we conducted a multicenter retrospective study. Methods We reviewed 478 men who underwent radical prostatectomy for clinically localized prostate cancer. All of the patients were followed up for at least 5 years. The cohort was then divided into three groups; no recurrence group, recurrence <5 years after surgery group and recurrence ≥5 years after surgery group. The background characteristics of each group were compared using the χ2 test. A Cox multivariate regression analysis was performed to determine the predictors of biochemical recurrence in each period. Results Biochemical recurrence occurred in 135 men. In 113 (84%) of the patients, biochemical recurrence occurred at <5 years after surgery; in 22 (16%), it occurred at ≥5 years after surgery. The proportion of men with a low preoperative prostate-specific antigen level was significantly larger in the latter group (P = 0.0023). A preoperative prostate-specific antigen level and a positive surgical margin were significant predictors of biochemical recurrence at <5 years after surgery (hazard ratio: 1.03 and 3.20). A positive surgical margin was also a significant predictor of biochemical recurrence at ≥5 years after surgery (hazard ratio: 3.03); however, a high preoperative prostate-specific antigen level was not. Conclusions Biochemical recurrence occurred at ≥5 years after surgery in 16% of the patients. A positive surgical margin predicted biochemical recurrence in both the early and late periods.
Collapse
Affiliation(s)
- Takahito Negishi
- Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka
| | - Kentarou Kuroiwa
- Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki
| | - Yoshifumi Hori
- Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki
| | | | - Hiroshi Uchino
- Department of Urology, Saga-Ken Medical Center Koseikan, Saga, Japan
| | - Noriaki Tokuda
- Department of Urology, Saga-Ken Medical Center Koseikan, Saga, Japan
| | - Nobuki Furubayashi
- Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka
| | - Kei Nagase
- Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka
| | - Hidenori Iwai
- Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka
| | - Motonobu Nakamura
- Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka
| |
Collapse
|
2
|
Reese AC. Clinical and Pathologic Staging of Prostate Cancer. Prostate Cancer 2016. [DOI: 10.1016/b978-0-12-800077-9.00039-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
3
|
Richters A, Derks J, Fossion LMCL, Kil PJM, Verhoeven RHA, Aarts MJ. Presence and Number of Positive Surgical Margins after Radical Prostatectomy for Prostate Cancer: Effect on Oncological Outcome in a Population-Based Cohort. Urol Int 2015; 95:472-7. [PMID: 26523366 DOI: 10.1159/000441012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2015] [Accepted: 09/09/2015] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Additional insight in the occurrence and number of positive surgical margins (PSM) and the potential consequences is needed, since earlier studies show divergent results. This study aims at investigating the effect of the presence and number of PSM on oncological outcomes. METHODS Retrospective population-based cohort study including 648 consecutive prostate cancer patients who underwent RP in the Southern Netherlands in 2006-2008. The effect of PSM on risk of treatment failure, defined by either biochemical recurrence or necessity of any additional therapy (Cox regression), was evaluated. RESULTS PSM were observed in 39%; 11% had multiple PSM. Treatment failure was observed in 26% of all patients. Multivariably, the presence (hazard ratio 2.5) and number of PSM (hazard ratios: single 2.3; multiple 3.1) were independently associated with higher treatment failure rates, unlike location of PSM. CONCLUSIONS Treatment failure rates are high among patients with PSM, especially in those with multiple PSM. This needs to be taken into account when decisions are made on the applicability of the adjuvant and salvage therapy.
Collapse
Affiliation(s)
- Anke Richters
- Netherlands Cancer Registry/Netherlands Comprehensive Cancer Organisation (IKNL), Department of Research, Utrecht, The Netherlands
| | | | | | | | | | | |
Collapse
|
4
|
Graefen M, Schlomm T, Sauter G, Huland H. Detailed Quantification of High-grade Cancer Allows Precise Prediction of Prostate Cancer Prognosis. Eur Urol 2015; 69:436-7. [PMID: 26443431 DOI: 10.1016/j.eururo.2015.09.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2015] [Accepted: 09/10/2015] [Indexed: 10/22/2022]
Affiliation(s)
- Markus Graefen
- Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
| | - Thorsten Schlomm
- Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Guido Sauter
- Institute of Pathology, Prostate Cancer Center and Section for Translational Prostate Cancer Research at the Clinic of Urology at University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Hartwig Huland
- Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
5
|
Skarecky DW, Brenner M, Rajan SS, Rodriguez E, Narula N, Melgoza F, Ahlering TE. Zero positive surgical margins after radical prostatectomy: is the end in sight? Expert Rev Med Devices 2014; 5:709-17. [DOI: 10.1586/17434440.5.6.709] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Douglas W Skarecky
- Department of Urology, University of California at Irvine, Orange, CA, USA
| | - Matthew Brenner
- Department of Medicine, University of California at Irvine, Orange, CA, USA
| | - Sudhir S Rajan
- Department of Medicine, University of California at Irvine, Orange, CA, USA
| | - Esequiel Rodriguez
- Department of Urology, University of California at Irvine, Orange, CA, USA
| | - Navneet Narula
- Department of Pathology, University of California at Irvine, Orange, CA, USA
| | - Frank Melgoza
- Department of Pathology, University of California at Irvine, Orange, CA, USA
| | - Thomas E Ahlering
- Department of Urology, University of California, Irvine Medical Center, 333 City Blvd West, Suite 2100, Orange, CA 92868, USA
| |
Collapse
|
6
|
Rouanne M, Rode J, Campeggi A, Allory Y, Vordos D, Hoznek A, Abbou CC, De La Taille A, Salomon L. Long-term impact of positive surgical margins on biochemical recurrence after radical prostatectomy: ten years of follow-up. Scand J Urol 2013; 48:131-7. [PMID: 23883410 DOI: 10.3109/21681805.2013.813067] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVE Positive surgical margins (PSMs) in men undergoing radical prostatectomy (RP) for prostate cancer are associated with an increased risk of biochemical recurrence. This study evaluated the long-term (>10 year) impact of PSMs on biochemical recurrence after RP in adjuvant treatment-naïve pT2-pT4 N0 men and determined predictors of prostate-specific antigen (PSA) failure. MATERIAL AND METHODS The institutional registry of 1276 patients who underwent RP at Henri Mondor Hospital from 1988 to 2001 was reviewed, identifying 403 patients with regular follow-up at the time of analysis. The study included 108 patients with PSMs who did not receive neoadjuvant or adjuvant therapy before PSA relapse. Median follow-up was 12.2 years. PSA failure was defined by a PSA rising by more than 0.2 ng/ml and biochemical recurrence-free survival (RFS) was estimated using the Kaplan-Meier method. Cox proportional hazard regression models were used to analyse clinicopathological variables associated with biochemical recurrence. RESULTS Biochemical recurrence 10 years after RP was 33.5% for patients regardless of the margin status. The 10-year biochemical RFS was 73% in men with negative margins compared to 49% in the case of PSM (p < 0.001). In multivariate analysis, margin status was a significantly predictive for PSA failure (hazard ratio 1.46, p = 0.04). After stratification by pathological stage, margin status was significantly predictive for biochemical RFS in pT2 (p < 0.001) and pT3a (p < 0.001), whereas the impact of PSM did not reach significance in pT3b (p = 0.16). CONCLUSIONS After 10-year follow-up, PSMs remain an independent risk factor of biochemical RFS after RP with less relevant impact in pT3b disease. Randomized prospective trials are needed to determine the place of adjuvant versus delayed radiotherapy.
Collapse
|
7
|
Robotic-assisted radical prostatectomy after the first decade: surgical evolution or new paradigm. ISRN UROLOGY 2013; 2013:157379. [PMID: 23691367 PMCID: PMC3649202 DOI: 10.1155/2013/157379] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/10/2013] [Accepted: 02/07/2013] [Indexed: 12/16/2022]
Abstract
Early studies indicate that robotic-assisted radical prostatectomy (RARP) has promising short-term outcomes; however, RARP is beyond its infancy, and the long-term report cards are now beginning. The important paradigm shift introduced by RARP is the reevaluation of the entire open radical prostatectomy experience in surgical technique by minimizing blood loss and complications, maximizing cancer free outcomes, and a renewed assault in preserving quality of life outcomes by many novel mechanisms. RARP provides a new technical “canvas” for surgical masters to create upon, and in ten years, has reinvigorated a 100-year-old “gold standard” surgery.
Collapse
|
8
|
Comploj E, Pycha A. Experience with radical perineal prostatectomy in the treatment of localized prostate cancer. Ther Adv Urol 2012; 4:125-31. [PMID: 22654964 PMCID: PMC3361748 DOI: 10.1177/1756287212441497] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Radical perineal prostatectomy is an alternative to the retropubic, robotic-assisted or the laparoscopic approach and it is one of the oldest surgical procedures for prostate cancer, but its use has declined over the past 30 years. The desire for lower morbidity, short hospital stay, and decreased costs has resulted in a renaissance of radical perineal prostatectomy. The combination of low morbidity, short hospital stay, and low economic costs brought to a renaissance of radical perineal prostatectomy.
Collapse
Affiliation(s)
- Evi Comploj
- Department of Urology, General Hospital of Bolzano, Lorenz Böhler Street 5 (BZ), 39100 Bolzano, Italy
| | | |
Collapse
|
9
|
Fryczkowski M, Bryniarski P, Szczębara M, Suchodolski M, Paradysz A. The impact of adjuvant therapy in patients with biochemical recurrence on prostate cancer progression and mortality five years after radical prostatectomy. Cent European J Urol 2011; 64:218-22. [PMID: 24578897 PMCID: PMC3921737 DOI: 10.5173/ceju.2011.04.art6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2011] [Revised: 07/02/2011] [Accepted: 07/28/2011] [Indexed: 11/22/2022] Open
Abstract
INTRODUCTION The clinical significance of biochemical recurrence (BCR) after radical prostatectomy (RP) due to prostate cancer (PCa) is not unambiguous, sometimes being independent from the real progression. BCR is followed by a greater risk of adverse events and almost always results with the necessity for implementation of adjuvant therapy (AT). The aim of the following study was to examine the impact of AT in patients with BCR together with PCa progression and mortality 5-years after RP. MATERIAL AND METHODS Two hundred forty-seven patients after RP, who were treated in the period from 1995 to 2009, underwent the retrospective analysis. They were divided into three groups according to the applied AT after prior BCR diagnosis. The first group (n - 39) included patients treated with radiotherapy, along with hormonotherapy. The second group (n - 63) covers patients receiving hormonotherapy only. The third group (n - 145) consists of patients without BCR. Five-year general and disease-specific survival was evaluated and choice prognostic factors were compared. RESULTS Five-year overall survival was 74.2% in group I, 88.3% in group II, and 98.7% in group III. Diseasespecific survival was: 76.9%, 90.5%, and 100% (p = 0.001), respectively. BCR was diagnosed in 102 (41.5%) patients; while in another 24 (23.5%) of them progression was diagnosed after the AT was applied. CONCLUSIONS The risk of BCR 5-years after RP is greater in patients with high initial concentration of PSA, higher Gleason score, and clinical advancement. Five-year overall and disease-specific survivals are higher among patients after hormonotherapy alone compared to those after both radio- and hormonotherapy.
Collapse
Affiliation(s)
| | - Piotr Bryniarski
- Department of Urology, Medical University of Silesia in Katowice, Zabrze, Poland
| | - Maciej Szczębara
- Department of Urology, Medical University of Silesia in Katowice, Zabrze, Poland
| | - Marian Suchodolski
- Department of Urology, Medical University of Silesia in Katowice, Zabrze, Poland
| | - Andrzej Paradysz
- Department of Urology, Medical University of Silesia in Katowice, Zabrze, Poland
| |
Collapse
|
10
|
Donovan MJ, Khan FM, Powell D, Bayer-Zubek V, Cordon-Cardo C, Costa J, Eastham J, Scardino P. Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery. BJU Int 2011; 109:40-5. [PMID: 21771247 DOI: 10.1111/j.1464-410x.2011.10398.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To compare the performance of a systems-based risk assessment tool with standard defined risk groups and the 10-year postoperative nomogram for predicting disease progression, including biochemical relapse and clinical (systemic) failure. PATIENTS AND METHODS Clinical variables, biometric profiles and outcome results from a training cohort comprising 373 patients in a published postoperative systems-based prognostic model were obtained. Patients were stratified according to D'Amico standard risk groups, Kattan 10-year postoperative nomogram and prognostic scores from the postoperative tissue model. The association of pathological variables and calculated risk groups with biochemical recurrence and clinical (systemic) failure was assessed using the concordance index (C-index) and hazard ratio (HR). RESULTS Systems-based post-prostatectomy models to predict significant disease progression (post-treatment clinical failure) were more accurate than the D'Amico defined risk groups and the Kattan 10-year postoperative nomogram (systems model: C-index, 0.84; HR, 17.46; P < 0.001 vs D'Amico: C-index, 0.73; HR, 11; P = 0.001; 10-year nomogram: C-index, 0.79; HR, 5.06; P < 0.001). The systems models were also more accurate than standard risk groups for predicting prostate-specific antigen recurrence (systems model: C-index, 0.76; HR, 8.94; P < 0.001 vs D'Amico C- index, 0.70; HR, 4.67; P < 0.001) and showed incremental improvement over the 10-year postoperative nomogram (C-index, 0.75; HR, 5.83; P < 0.001). The postoperative tissue model provided additional risk discrimination over surgical margin status and extracapsular extension for predicting disease outcome, and was most significant for the clinical (systemic) failure endpoint (surgical margin: C-index, 0.58; HR, 1.57; P= 0.2; extracapsular extension: C-index, 0.62; HR, 2.06; P = 0.04). CONCLUSIONS Risk assessment models that incorporate characteristics from the patient's own tumour specimen are more accurate than clinical-only nomograms for predicting significant disease outcome. Systems-based tools should provide useful information concerning the appropriate receipt of adjuvant therapy in the post-surgical setting.
Collapse
|
11
|
Schlomm T, Chun FK, Erbersdobler A. From gene to clinic: TMA-based clinical validation of molecular markers in prostate cancer. Methods Mol Biol 2010; 664:177-89. [PMID: 20690063 DOI: 10.1007/978-1-60761-806-5_17] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
Current high-throughput screening techniques using DNA arrays have identified hundreds of new candidate biomarkers for diagnosis and risk prediction of prostate cancer. Large-scale analysis of clinical prostate cancer specimens is a key prerequisite for the validation of these genes. We have constructed a tissue microarray from more than 2,500 prostate cancers with full histo-pathological and clinical long-term follow-up data and analyzed expression and gene copy number patterns of 16 different candidate markers for their ability to predict prostate cancer progression and patient prognosis. The best candidates were used to extend established clinical prediction tools (nomograms) that were based on nonmolecular data only, such as prostate-specific antigene (PSA), clinical stage, and histological grading (Gleason grade). Using this approach, we could identify ANXA3 as an independent marker, which was capable of increasing the accuracy of the clinical nomogram, thereby fulfilling the criteria of a novel prognostic prostate cancer marker. This approach of integrating large-scale clinical and molecular variables may provide a new paradigm for the use of molecular profiling to predict the clinical outcome in prostate cancer.
Collapse
Affiliation(s)
- Thorsten Schlomm
- Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
| | | | | |
Collapse
|
12
|
Anastasiou I, Tyritzis SI, Adamakis I, Mitropoulos D, Stravodimos KG, Katafigiotis I, Balangas A, Kollias A, Pavlakis K, Constantinides CA. Prognostic factors identifying biochemical recurrence in patients with positive margins after radical prostatectomy. Int Urol Nephrol 2010; 43:715-20. [DOI: 10.1007/s11255-010-9859-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2010] [Accepted: 09/29/2010] [Indexed: 11/29/2022]
|
13
|
Zakian KL, Hricak H, Ishill N, Reuter VE, Eberhardt S, Moskowitz CS, Shukla-Dave A, Wang L, Scardino PT, Eastham JA, Koutcher JA. An exploratory study of endorectal magnetic resonance imaging and spectroscopy of the prostate as preoperative predictive biomarkers of biochemical relapse after radical prostatectomy. J Urol 2010; 184:2320-7. [PMID: 20952035 DOI: 10.1016/j.juro.2010.07.037] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2010] [Indexed: 10/18/2022]
Abstract
PURPOSE Radical prostatectomy has significant side effects. Preoperative information predicting its long-term outcome would be valuable to patients and physicians. We determined whether pretreatment endorectal magnetic resonance imaging/magnetic resonance spectroscopic imaging predicts biochemical recurrence after radical prostatectomy. MATERIALS AND METHODS Of 202 patients who underwent endorectal magnetic resonance imaging/magnetic resonance spectroscopic imaging from January 2000 to December 2002 before radical prostatectomy 130 satisfied study inclusion criteria and were included in analysis. We compared imaging factors with potential predictive capability to biochemical recurrence data, including magnetic resonance imaging risk score based on local disease extent and magnetic resonance spectroscopic imaging index lesion characteristics, such as the number of voxels and degree of metabolic abnormality (magnetic resonance spectroscopic imaging grade). We evaluated associations of these imaging variables with time to biochemical recurrence by Cox proportional hazards regression adjusted for known predictors of biochemical recurrence, such as stage, grade and prostate specific antigen. RESULTS At a median 68-month followup there were 26 biochemical failures. Risk score, lesion volume and high grade voxels each correlated with time to biochemical recurrence. In a model combining clinical parameters risk score, lesion volume and at least 1 high grade voxel the magnetic resonance spectroscopic imaging variables remained significant but the magnetic resonance imaging score dropped out. CONCLUSIONS Index lesion volume on magnetic resonance spectroscopic imaging and high grade magnetic resonance spectroscopic imaging voxels correlate with time to biochemical recurrence after radical prostatectomy even when adjusted for clinical data. Results suggest the preoperative predictive usefulness of endorectal magnetic resonance imaging/magnetic resonance spectroscopic imaging in patients considering radical prostatectomy.
Collapse
Affiliation(s)
- Kristen L Zakian
- Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Rajab R, Fisher G, Kattan MW, Foster CS, Oliver T, Møller H, Reuter V, Scardino P, Cuzick J, Berney DM. Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort. Virchows Arch 2010; 457:547-53. [PMID: 20827488 DOI: 10.1007/s00428-010-0971-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2010] [Revised: 08/23/2010] [Accepted: 08/29/2010] [Indexed: 10/19/2022]
Abstract
The optimal method for measuring cancer extent in prostate biopsy specimens is unknown. Seven hundred forty-four patients diagnosed between 1990 and 1996 with prostate cancer and managed conservatively were identified. The clinical end point was death from prostate cancer. The extent of cancer was measured in terms of number of cancer cores (NCC), percentage of cores with cancer (PCC), total length of cancer (LCC) and percentage length of cancer in the cores (PLC). These were correlated with prostate cancer mortality, in univariate and multivariate analysis including Gleason score and prostate-specific antigen (PSA). All extent of cancer variables were significant predictors of prostate cancer death on univariate analysis: NCC, hazard ration (HR) = 1.15, 95% confidence interval (CI) = 1.04-1.28, P = 0.011; PPC, HR = 1.01, 95% CI = 1.01-1.02, P < 0.0001; LCC, HR = 1.02, 95% CI = 1.01-1.03, P = 0.002; PLC, HR = 1.01, 95% CI = 1.01-1.02, P = 0.0001. In multivariate analysis including Gleason score and baseline PSA, PCC and PLC were both independently significant P = 0.004 and P = 0.012, respectively, and added further information to that provided by PSA and Gleason score, whereas NNC and LCC were no longer significant (P = 0.5 and P = 0.3 respectively). In a final model, including both extent of cancer variables, PCC was the stronger, adding more value than PLC (χ² (1df) = 7.8, P = 0.005, χ² (1df) = 0.5, P = 0.48 respectively). Measurements of disease burden in needle biopsy specimens are significant predictors of prostate-cancer-related death. The percentage of positive cores appeared the strongest predictor and was stronger than percentage length of cancer in the cores.
Collapse
Affiliation(s)
- Ramzi Rajab
- Centre for Molecular Oncology and Imaging, Queen Mary University of London, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Zattoni F, Gigli F. Radicai Prostatectomy: Local Recurrence and Persistence of Disease. Is it Possible to Hypothesize any Responsibility of the Surgeon? Urologia 2010. [DOI: 10.1177/039156031007700301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Radical prostatectomy (RP) represents the most frequently chosen therapeutic option for treating newly diagnosed localized prostate cancer. Cancer recurrence after surgery is linked to biologic variables. But are these the only ones that must be considered to give an explanation of a possible local or distal recurrence, or can it also admit the possibility that an incorrectly conducted surgery has a negative role in the unfavorable evolution after PR? Prostate cancer recurrence, as a matter of fact, is related also to surgical technique. The PR, by definition is a surgical, potentially complicated act. Surgery outcomes depend on a whole serires of factors: the surgeon's ability, and the way the surgical procedure is conducted, play an essential role. Here we evaluate the role of biological and surgical factors on biochemical recurrence.
Collapse
|
16
|
Shariat SF, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT. Critical review of prostate cancer predictive tools. Future Oncol 2010; 5:1555-84. [PMID: 20001796 DOI: 10.2217/fon.09.121] [Citation(s) in RCA: 136] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Prostate cancer is a very complex disease, and the decision-making process requires the clinician to balance clinical benefits, life expectancy, comorbidities and potential treatment-related side effects. Accurate prediction of clinical outcomes may help in the difficult process of making decisions related to prostate cancer. In this review, we discuss attributes of predictive tools and systematically review those available for prostate cancer. Types of tools include probability formulas, look-up and propensity scoring tables, risk-class stratification prediction tools, classification and regression tree analysis, nomograms and artificial neural networks. Criteria to evaluate tools include discrimination, calibration, generalizability, level of complexity, decision analysis and ability to account for competing risks and conditional probabilities. The available predictive tools and their features, with a focus on nomograms, are described. While some tools are well-calibrated, few have been externally validated or directly compared with other tools. In addition, the clinical consequences of applying predictive tools need thorough assessment. Nevertheless, predictive tools can facilitate medical decision-making by showing patients tailored predictions of their outcomes with various alternatives. Additionally, accurate tools may improve clinical trial design.
Collapse
Affiliation(s)
- Shahrokh F Shariat
- Department of Surgery, Urology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | |
Collapse
|
17
|
Alkhateeb S, Alibhai S, Fleshner N, Finelli A, Jewett M, Zlotta A, Nesbitt M, Lockwood G, Trachtenberg J. Impact of positive surgical margins after radical prostatectomy differs by disease risk group. J Urol 2010; 183:145-50. [PMID: 19913824 DOI: 10.1016/j.juro.2009.08.132] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2009] [Indexed: 11/15/2022]
Abstract
PURPOSE Positive surgical margins have a negative impact on disease outcomes after radical prostatectomy, yet their prognostic value may vary depending on specific pathological characteristics. We examined the relationship of positive surgical margins to biochemical progression according to several clinicopathological features. MATERIALS AND METHODS We analyzed data from 1,268 patients who underwent radical prostatectomy for clinically localized prostate cancer at our center between 1992 and 2008, and did not receive any neoadjuvant or adjuvant treatment. We examined the relation of age, pretreatment prostate specific antigen, pathological T stage, radical prostatectomy Gleason score, disease risk group and surgical margin status to biochemical progression-free survival. RESULTS The overall positive surgical margin rate was 20.8% and median followup was 79 months. The impact of positive surgical margins was dependent on risk group. Biochemical progression-free survival was 99.6% for the negative surgical margin group vs 94.9% for the positive surgical margin group in low risk disease (log rank p = 0.53), 93.5% for the negative surgical margin group vs 83% for the positive surgical margin group in intermediate risk disease (log rank p <0.001) and 78.5% for the negative surgical margin group vs 57.1% for the positive surgical margin group in high risk disease (log rank p = 0.003). These differences remained significant in a multivariate Cox regression model adjusting for other clinicopathological features. CONCLUSIONS Positive surgical margins are an independent predictor of biochemical progression in patients with intermediate and high risk prostate cancer. Patients with low risk disease have a favorable long-term outcome regardless of margin status and may be candidates for expectant management even with positive surgical margins, sparing them the side effects and costs of treatment.
Collapse
Affiliation(s)
- Sultan Alkhateeb
- Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Nguyen CT, Kattan MW. Development of a prostate cancer metagram: a solution to the dilemma of which prediction tool to use in patient counseling. Cancer 2009; 115:3039-45. [PMID: 19544545 DOI: 10.1002/cncr.24355] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Many treatment options are available to the human with clinically localized prostate cancer, including surgery, radiation, and even active surveillance. To the authors' knowledge, there is no consensus on the optimal management of this patient population, with most clinicians tending to recommend the treatment with which they are most familiar. Effective patient counseling allowing informed decision making can be best achieved with a formalized system that offers accurate predictions of outcomes for all available treatment approaches. The authors organized the currently available prostate cancer prediction tools toward the formation of a metagram that can be used to tailor management to the individual patient. A comprehensive review of the literature was performed to identify published prediction tools intended for use in prostate cancer. Tools were categorized by a combination of treatment modality and the outcome being predicted, and incorporated into a metagram constructed of 16 different treatment options and 10 outcomes related to cancer control, survival, and morbidity. A search of the literature revealed 44 prostate cancer prediction tools that assessed at least 1 of the 160 treatment/outcome combinations that comprise the metagram. Only 31 cells of the metagram were populated with currently available tools. Prediction tools offer the most accurate estimates of outcomes in prostate cancer, but their current role in patient counseling is complicated by the large number of existing tools, as well as a lack of comparative data. To address this, the authors incorporated the most relevant prediction tools currently available into a prostate cancer metagram that may offer evidence-based and individualized predictions for multiple endpoints after all available treatment options in clinically localized prostate cancer. The metagram also reveals areas of deficiency in the current catalog of prediction tools. Many more prediction tools are needed. Cancer 2009;115(13 suppl):3039-45. (c) 2009 American Cancer Society.
Collapse
Affiliation(s)
- Carvell T Nguyen
- Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA
| | | |
Collapse
|
19
|
Sæther T, Sørlien LT, Viset T, Lydersen S, Angelsen A. Are positive surgical margins in radical prostatectomy specimens an independent prognostic marker? ACTA ACUST UNITED AC 2009; 42:514-21. [DOI: 10.1080/00365590802299585] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Thorstein Sæther
- Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
| | - Lars Tjugum Sørlien
- Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
| | | | - Stian Lydersen
- Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
| | - Anders Angelsen
- Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
- Urology, St Olav's Hospital, University Hospital of Trondheim, Trondheim, Norway
| |
Collapse
|
20
|
Graham SM, Holzbeierlein JM. Adjuvant radiation therapy after radical prostatectomy: when is it indicated? Curr Urol Rep 2009; 10:194-8. [PMID: 19371476 DOI: 10.1007/s11934-009-0033-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Radical prostatectomy is the most commonly used treatment option in the United States for men with clinically localized prostate cancer. Up to 30% of these patients, particularly those with adverse pathological risk factors, will develop a biochemical recurrence within 10 years. Patients with a biochemical recurrence have a higher rate of local recurrence and cancer-specific mortality. Current accepted treatment options include salvage radiation therapy, hormone therapy, or a combination of both, depending on whether the disease recurrence is biochemical, local, or systemic. The role of adjuvant radiation therapy (ART) after prostatectomy in patients with adverse pathological risk factors prior to biochemical or clinical recurrence is unclear. Recent randomized trials have demonstrated that ART significantly improves multiple patient outcomes, including overall and cancer-specific survival, without major untoward effects. The evidence in support of using ART is evolving with the long-term follow-up of several long-term prospective trials. The decision to use ART should be based on the patient's pathological characteristics, clinical status, side effects, and open communication between the patient and provider.
Collapse
Affiliation(s)
- Stephen M Graham
- Department of Urology, University of Kansas Medical Center, Kansas City, KS 66160, USA
| | | |
Collapse
|
21
|
Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated catalog of prostate cancer predictive tools. Cancer 2008; 113:3075-99. [PMID: 18823041 DOI: 10.1002/cncr.23908] [Citation(s) in RCA: 216] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Shahrokh F Shariat
- Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
| | | | | | | |
Collapse
|
22
|
Yossepowitch O, Bjartell A, Eastham JA, Graefen M, Guillonneau BD, Karakiewicz PI, Montironi R, Montorsi F. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 2008; 55:87-99. [PMID: 18838211 DOI: 10.1016/j.eururo.2008.09.051] [Citation(s) in RCA: 182] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2008] [Accepted: 09/23/2008] [Indexed: 11/28/2022]
Abstract
CONTEXT This review focuses on positive surgical margins (PSM) in radical prostatectomy (RP). OBJECTIVE To address the etiology, incidence, and oncologic impact of PSM and discuss technical points to help surgeons minimize their positive margin rate. An evidence-based approach to assist clinicians in counseling patients with a PSM is provided. EVIDENCE ACQUISITION A literature search in English was performed using the National Library of Medicine database and the following key words: prostate cancer, surgical margins, and radical prostatectomy. Seven hundred sixty-eight references were scrutinized, and 73 were selected for rigorous review based on their pertinence, study size, and overall contribution to the field. EVIDENCE SYNTHESIS In contemporary series, PSM are reported in 11-38% of patients undergoing RP. Although variability exists in the pathologic interpretation of surgical margins, PSM are associated with an increased hazard of biochemical recurrence (BCR) and local disease recurrence as well as the need for secondary cancer treatment. A posterolateral PSM appears to confer the greatest risk of recurrence, whereas the prognostic significance of positive apical margins remains controversial. The role of preoperative imaging and intraoperative frozen section analysis are being investigated to reduce margin positivity rates. Level-1 evidence indicates that adjuvant radiotherapy (RT) in men with PSM reduces BCR rates and clinical progression and possibly improves overall survival (OS). CONCLUSIONS PSM in RP specimens are uniformly considered an adverse outcome. Regardless of approach (open or laparoscopic), attention to surgical detail is essential to minimize rates. For patients with a PSM destined to experience a cancer recurrence, RT is the only established treatment with curative potential. A randomized trial in patients with PSM comparing immediate postoperative RT to salvage RT is critically needed before definitive recommendations can be made.
Collapse
|
23
|
Abstract
PURPOSE OF REVIEW We created an inventory of current predictive tools available for prostate cancer. This review may serve as an initial step toward a comprehensive reference guide for physicians to locate published nomograms that apply to the clinical decision in question. Using MEDLINE a literature search was performed on prostate cancer predictive tools from January 1966 to November 2007. We describe the patient populations to which they apply and the outcomes predicted, and record their individual characteristics. RECENT FINDINGS The literature search generated 111 published prediction tools that may be applied to patients in various clinical stages of disease. Of the 111 prediction tools, only 69 had undergone validation. We present an inventory of models with input variables, prediction form, number of patients used to develop the prediction tools, the outcome being predicted, prediction tool-specific features, predictive accuracy, and whether validation was performed. SUMMARY Decision rules, such as nomograms, provide evidence-based and at the same time individualized predictions of the outcome of interest. Such predictions have been repeatedly shown to be more accurate than those of clinicians, regardless of their level of expertise. Accurate risk estimates are also required for clinical trial design, to ensure homogeneous high-risk patient groups for whom new cancer therapeutics will be investigated.
Collapse
|
24
|
Brimo F, Vollmer RT, Corcos J, Kotar K, Bégin LR, Humphrey PA, Bismar TA. Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. Histopathology 2008; 53:177-83. [DOI: 10.1111/j.1365-2559.2008.03087.x] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
25
|
Swindle P, Eastham JA, Ohori M, Kattan MW, Wheeler T, Maru N, Slawin K, Scardino PT. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 2008; 179:S47-51. [PMID: 18405751 DOI: 10.1016/j.juro.2008.03.137] [Citation(s) in RCA: 102] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2004] [Indexed: 11/15/2022]
Abstract
PURPOSE The prognostic significance of positive surgical margins (PSM) in radical prostatectomy (RP) specimens remains unclear. While most studies have concluded that a PSM is an independent adverse prognostic factor, others report that surgical margin status has no effect on prognosis. One reason for these discordant conclusions is the variable number of patients with a PSM who receive adjuvant therapy and the differing statistical methods used to account for the effects of the time course of adjuvant treatment on recurrence. We evaluated the prognostic significance of PSMs using multiple methods of analysis accounting for patients who received adjuvant therapy. MATERIALS AND METHODS We analyzed 1,389 consecutive patients with clinical stage T1-3 prostate cancer treated with RP by 2 surgeons from 1983 to 2000. Of 179 patients with a PSM, 37 received adjuvant therapy (AT), 29 radiation therapy and 8 received hormonal therapy. Because the method used to account for men receiving AT can affect the outcome of the analysis, data were analyzed by the Cox proportional hazards technique accounting for patients receiving AT using 5 methods: 1) exclusion, 2) inclusion (AT ignored), 3) censoring at time of AT, 4) failing at time of AT and 5) considering AT as a time dependent covariate. RESULTS Overall 179 patients (12.9%) had a PSM, including 6.8% of 847 patients with pT2 and 23% of 522 patients with pT3 disease. A PSM was a significant predictor of cancer recurrence when analyzed using methods 1, 3, 4 and 5 (p=0.005, p=0.014, p=0.0005, p=0.002, respectively). However, it was not a predictor of recurrence using method 2 in which AT was ignored (p=0.283). Using method 5 multivariate analysis demonstrated that a PSM (p=0.002) was an independent predictor of 10-year progression-free probability (PFP) along with Gleason score (p=0.0005), extracapsular extension (p=0.0005), seminal vesicle invasion (p <0.0005), positive lymph nodes (p <0.0005) and preoperative serum prostate specific antigen (p <0.0001). Using method 5 the 10-year PFP was 58% +/- 12% and 81% +/- 3% for patients with and without a PSM, respectively (p <0.00005). The relative risk of recurrence in men with a PSM using method 5 was 1.52 (95% confidence interval 1.06-2.16). CONCLUSIONS We confirm that a PSM has a significant adverse impact on PFP after RP in multivariate analysis using multiple statistical methods to account for patients who received AT. While prostate cancer screening strategies have resulted in a majority of men having organ confined disease at RP, surgeons should continue to strive to reduce the rate of positive surgical margins to improve cancer control outcomes.
Collapse
Affiliation(s)
- Peter Swindle
- Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary evaluation of the D'amico risk classification of prostate cancer. Urology 2008; 70:931-5. [PMID: 18068450 DOI: 10.1016/j.urology.2007.08.055] [Citation(s) in RCA: 97] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2007] [Revised: 07/03/2007] [Accepted: 08/28/2007] [Indexed: 12/13/2022]
Abstract
OBJECTIVES In 1998, D'Amico et al. suggested a model stratifying patients with prostate cancer into those with low, intermediate, or high-risk of biochemical recurrence after surgery according to the clinical TNM stage, biopsy Gleason score, and preoperative prostate-specific antigen level. We studied the performance and clinical relevance of this classification system over time, in the context of the stage migration seen in the contemporary era, using data from a high-volume, tertiary referral center. METHOD From 1984 to 2005, 6652 men underwent radical prostatectomy at our institution for clinically localized prostate cancer (clinical Stage T1c-T2c) with follow-up information available and no neoadjuvant or adjuvant therapy before biochemical recurrence. Biochemical recurrence-free survival (BRFS) was estimated using the Kaplan-Meier method, and the BRFS rates between the D'Amico risk groups and by era were compared using the log-rank statistic. Finally, the distribution of patients among the three groups was compared over time. RESULTS The 5-year BRFS rate was 84.6% overall and 94.5%, 76.6%, and 54.6% for the low, intermediate, and high-risk groups, respectively (P <0.0001). In the contemporary era, a very small fraction (4.9%) of patients undergoing radical prostatectomy at our institution were in the high-risk group, with most (67.7%) in the low-risk group (P <0.001). CONCLUSIONS The D'Amico classification system continues to stratify men into risk groups with statistically significant differences in BRFS. However, the major shift in the distribution of patients among the three risk groups over time suggests that the clinical relevance of this classification scheme may be limited and diminishing in the contemporary era.
Collapse
Affiliation(s)
- David J Hernandez
- Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA.
| | | | | | | |
Collapse
|
27
|
Briganti A, Chun FKH, Hutterer GC, Gallina A, Shariat SF, Salonia A, Scattoni V, Valiquette L, Montorsi F, Rigatti P, Graefen M, Huland H, Karakiewicz PI. Systematic Assessment of the Ability of the Number and Percentage of Positive Biopsy Cores to Predict Pathologic Stage and Biochemical Recurrence after Radical Prostatectomy. Eur Urol 2007; 52:733-43. [PMID: 17350750 DOI: 10.1016/j.eururo.2007.02.054] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2006] [Accepted: 02/23/2007] [Indexed: 11/29/2022]
Abstract
OBJECTIVES We hypothesized that the number and/or percentage of positive cores, proxies of tumor volume, could improve the ability to predict pathologic stages and/or biochemical recurrence (BCR). To test this hypothesis, we examined radical retropubic prostatectomy (RRP) data from three centers on two continents. MATERIAL AND METHODS Clinical data from men undergoing RRP at three different institutions were used to predict pathologic stages and BCR. Univariable and multivariable logistic analyses and Cox regression analyses were used. Predictive accuracy (PA) was assessed with the area under the receiver operating characteristics curve estimates, which were subjected to 200 bootstraps to reduce overfit bias. The statistical significance of PA gains was assessed with the Mantel-Haenszel test. RESULTS The number and the percentage of positive cores were independent predictors of virtually all pathologic stage outcomes and of BCR. In PA analyses, the percentage of positive cores improved the PA of pathologic stage predictions and of BCR predictions between 0.06% and 1.49%. Conversely, the number of positive cores improved the PA of pathologic stage predictions and of BCR predictions between 0.36% and 1.14%. CONCLUSIONS The information derived from biopsy cores is important and can improve the ability to predict pathologic stage and BCR. It appears that the percentage of cores is most helpful in stage predictions. Conversely, the number of cores appears to improve mostly BCR predictions. Consideration of both variables might not be helpful because of the similarity of information they encode.
Collapse
Affiliation(s)
- Alberto Briganti
- Department of Urology, Vita-Salute University San Raffaele, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Thompson RH, Blute ML, Slezak JM, Bergstralh EJ, Leibovich BC. Is the GPSM Scoring Algorithm for Patients With Prostate Cancer Valid in the Contemporary Era? J Urol 2007; 178:459-63; discussion 463. [PMID: 17561132 DOI: 10.1016/j.juro.2007.03.124] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2006] [Indexed: 10/23/2022]
Abstract
PURPOSE The GPSM (Gleason, prostate specific antigen, seminal vesicle and margin status) scoring algorithm is a user friendly model for predicting biochemical recurrence following radical retropubic prostatectomy. It was developed from patients who underwent radical retropubic prostatectomy from 1990 to 1993. We investigated the predictive ability of GPSM in the contemporary era. MATERIALS AND METHODS We identified 2,728 patients who underwent radical retropubic prostatectomy for prostate cancer from 1997 to 2000 at our institution. Cox proportional hazard regression models were used to develop multivariate scoring algorithms. Harrell's measure of concordance was used to compare the competing models. RESULTS In the contemporary era each GPSM feature remained significantly associated with biochemical recurrence in a multivariate model (each p <0.001). Harrell's measure of concordance for the algorithm was 0.706 vs 0.718 in the original study. After adjusting for GPSM on multivariate analysis Gleason primary 4/5 (p <0.001), DNA ploidy (p = 0.018) and tumor size (p <0.001) were associated with biochemical recurrence. However, none of these features increased Harrell's measure of concordance greater than 0.01 when added to the GPSM model. In addition, using the original 1990 to 1993 cohort, 495 patients with a GPSM score of 10 or greater were significantly more likely to die of prostate cancer compared with 2,169 with a GPSM score of less than 10 (at 15 years 13% vs 2%, HR 6.5, p <0.001). CONCLUSIONS The GPSM scoring algorithm is a simple predictive model that remains associated with biochemical recurrence in the contemporary era. In addition, to our knowledge the GPSM algorithm is the first nomogram associated with survival in patients with prostate cancer.
Collapse
Affiliation(s)
- R Houston Thompson
- Department of Urology and Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
| | | | | | | | | |
Collapse
|
29
|
Chun FKH, Karakiewicz PI, Briganti A, Walz J, Kattan MW, Huland H, Graefen M. A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. BJU Int 2007; 99:794-800. [PMID: 17378842 DOI: 10.1111/j.1464-410x.2006.06694.x] [Citation(s) in RCA: 99] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To evaluate several methods of predicting prostate cancer-related outcomes, i.e. nomograms, look-up tables, artificial neural networks (ANN), classification and regression tree (CART) analyses and risk-group stratification (RGS) models, all of which represent valid alternatives. METHODS We present four direct comparisons, where a nomogram was compared to either an ANN, a look-up table, a CART model or a RGS model. In all comparisons we assessed the predictive accuracy and performance characteristics of both models. RESULTS Nomograms have several advantages over ANN, look-up tables, CART and RGS models, the most fundamental being a higher predictive accuracy and better performance characteristics. CONCLUSION These results suggest that nomograms are more accurate and have better performance characteristics than their alternatives. However, ANN, look-up tables, CART analyses and RGS models all rely on methodologically sound and valid alternatives, which should not be abandoned.
Collapse
Affiliation(s)
- Felix K-H Chun
- Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
| | | | | | | | | | | | | |
Collapse
|
30
|
Schostak M, Krause H, Miller K, Schrader M, Kempkensteffen C, Kollermann J. Does the molecular staging in pelvic lymph nodes improve the detection of relevant prostate cancer metastases? An assessment after 6 years. BJU Int 2007; 99:1409-14. [PMID: 17428244 DOI: 10.1111/j.1464-410x.2007.06861.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
OBJECTIVE To assess the course of cancer-free survival and thus determine how reliably reverse transcriptase-polymerase chain reaction (RT-PCR) can detect prostate-specific antigen (PSA)-expressing cells, as patients with untreated lymph node-positive prostate cancer tend to have a poor prognosis, whereas those treated with radical prostatectomy (RP) and immediate adjuvant hormonal therapy show excellent local disease control and a disease-free survival comparable with that of patients with negative lymph nodes, but the detection of micrometastatic disease in pelvic lymph nodes remains a major challenge. PATIENTS AND METHODS Quantitative RT-PCR was used to detect PSA mRNA expression in total RNA of 457 pelvic lymph nodes from 70 patients who had RP (53 patients) or laparoscopic lymphadenectomy (17) at our clinic in 1999/2000. For this purpose, alternate sections of lymph node tissue were either snap-frozen for later RNA isolation or examined by standard histopathological methods. Clinicopathological data, adjuvant treatments and follow-up data were recorded for all patients. RESULTS After January 2006 (6-year observation period), 13 patients had no follow-up data, while 27 had biochemical (PSA) recurrence or other evidence of clinical progression (two died from prostate cancer), and 30 had no signs of recurrence. Compared to the 'reference' standard (histopathology), the PCR method had a sensitivity of 83% and a specificity of 66%. The method had a positive predictive value of 52% and a negative predictive value of 57%. CONCLUSION Considered alone, pelvic lymph node PSA RT-PCR does not predict the clinical course better than a histopathological assessment of lymph nodes. However, it also identifies some patients with negative histology who later show progression. When added to the pathological classification, PSA RT-PCR improves the detection rate of primary lymphatic dissemination.
Collapse
Affiliation(s)
- Martin Schostak
- Department of Urology, Charité- Campus Benjamin Franklin, Universitätsmedizin Berlin, Germany.
| | | | | | | | | | | |
Collapse
|
31
|
Vis AN, Roemeling S, Kranse R, Schröder FH, van der Kwast TH. Should We Replace the Gleason Score with the Amount of High-Grade Prostate Cancer? Eur Urol 2007; 51:931-9. [PMID: 16935413 DOI: 10.1016/j.eururo.2006.07.051] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2006] [Accepted: 07/28/2006] [Indexed: 11/25/2022]
Abstract
OBJECTIVES The stage and grade shift of currently diagnosed prostate cancer has led to a diminished prognostic power of the Gleason score system. We investigated the predictive value of the amount of high-grade cancer (Gleason growth patterns 4/5) in the biopsy for prostate-specific antigen (PSA) and clinical relapse after radical prostatectomy. METHODS PSA-tested participants (N=281) of the European Randomized Study of Screening for Prostate Cancer (ERSPC) who underwent radical prostatectomy were analyzed. Besides clinical features, and serum-PSA, histopathologic features as determined in the diagnostic biopsy and matching radical prostatectomy specimen were related to patient outcome. RESULTS At a median follow-up of 7 yr, 39 (13.9%), 24 (8.5%), and 12 (4.3%) patients had PSA >/=0.1 ng/ml, PSA >/=1.0 ng/ml, and clinical relapse after radical prostatectomy, respectively. Using Cox proportional hazards, PSA level (p=0.002), length of tumour (p=0.040), and length of high-grade cancer (p=0.006) in the biopsy, but not Gleason score, were independent prognostic factors for biochemical relapse (PSA >/=0.1 ng/ml) when assessed as continuous variables. In radical prostatectomies, the proportion of high-grade cancer (p<0.001) was most predictive of relapse (PSA >/=0.1 ng/ml). For PSA >/=1.0 ng/ml and clinical relapse, the amount of high-grade cancer, both in the biopsy specimen (p=0.016 and p=0.004, respectively) and radical prostatectomy specimen (p=0.002 and p=0.005, respectively), but not Gleason score, was an independent predictor. CONCLUSIONS In biopsy and radical prostatectomy specimens of surgically treated prostate cancer, the amount of high-grade cancer is superior to the Gleason grading system in predicting patient outcome. We propose that, in addition to the Gleason score, the amount of Gleason growth patterns 4/5 in the biopsy (whether absolute length or proportion) should be mentioned in the pathology report.
Collapse
Affiliation(s)
- André N Vis
- Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands.
| | | | | | | | | |
Collapse
|
32
|
Streszczenie. Rep Pract Oncol Radiother 2007. [DOI: 10.1016/s1507-1367(07)70955-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
33
|
Chun FKH, Briganti A, Antebi E, Graefen M, Currlin E, Steuber T, Schlomm T, Walz J, Haese A, Friedrich MG, Ahyai SA, Eichelberg C, Salomon G, Gallina A, Erbersdobler A, Perrotte P, Heinzer H, Huland H, Karakiewicz PI. Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients. BJU Int 2006; 98:1204-9. [PMID: 17034506 DOI: 10.1111/j.1464-410x.2006.06442.x] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To assess the association between surgical volume (SV) and the rate of positive surgical margins (PSM) after radical prostatectomy (RP) in a large single-institution European cohort of patients. PATIENTS AND METHODS In all, 2402 men had a RP by a group of 11 surgeons, all of whom were trained by the surgeon with the highest SV; all surgeons used the same surgical technique. Variables assessed before RP were prostate-specific antigen (PSA) level, clinical stage and biopsy Gleason sum; variables assessed after RP were PSA level, extracapsular extension, seminal vesicle invasion, lymph node invasion and pathological Gleason sum. These were used to predict the rate of PSM in models before or after RP. Multivariate models were complemented with SV to test its independent and multivariate statistical significance and to quantify its impact on the model's overall (and 200 bootstrap-corrected) predictive accuracy. RESULTS The mean (range) SV was 201 (1-1293) RPs; the mean (median, range) rate of PSM was 20.2 (21.4, 0-32.9)%. In multivariate models, SV was a highly statistically significant independent predictor of PSM (P < 0.001) and increased the predictive accuracy in multivariate models both before (2.0%) and after RP (1.5%, both P < 0.001). However, when the surgeon with the highest SV, who contributed to 1293 cases, was removed from the analyses, the multivariate independent prediction and the gains in predictive accuracy related to adding SV, disappeared in the models both before (P = 0.9, accuracy gain 0.1%) and after (P = 0.4, accuracy gain - 0.3%) RP. CONCLUSIONS These results indicate that patients treated by surgeons with a very high volume can expect to have a significantly lower rate of PSM, after accounting for clinical and pathological case-mix differences. However, SV is not a predictor of PSM when analyses are restricted to intermediate- and low-volume surgeons.
Collapse
Affiliation(s)
- Felix K-H Chun
- Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Graefen M. The Positive Surgical Margin after Radical Prostatectomy—Why do we Still not Really Know What it Means? Eur Urol 2006; 50:199-201. [PMID: 16624479 DOI: 10.1016/j.eururo.2006.02.016] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2006] [Accepted: 02/03/2006] [Indexed: 11/28/2022]
|
35
|
Ayyathurai R, Ananthakrishnan K, Rajasundaram R, Knight RJ, Toussi H, Srinivasan V. Predictive Ability of Partin Tables 2001 in a Welsh Population. Urol Int 2006; 76:217-22. [PMID: 16601382 DOI: 10.1159/000091622] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
OBJECTIVES Partin tables are widely used to select and counsel patients prior to radical surgery for prostate cancer. However, Partin tables have been developed in the USA which has a different ethnic mixture from that of North Wales. We aimed to assess Partin tables' predictive ability in a Welsh population. MATERIALS AND METHODS 193 patients underwent radical retropubic prostatectomy for clinically localized carcinoma of the prostate between April 1993 and July 2004 in a single institution in North Wales. Complete preoperative clinical staging information was available in 177 patients. Receiver operating characteristic curve analysis was used. RESULTS The mean patient age was 64 (48-73) years. Preoperative clinical staging distribution was: T1c 46.6% and T2 53.4%. 75% had organ-confined disease (TNM 1992). Extracapsular extension without seminal vesicle or lymph node involvement was seen in 13.5%. Nine percent had seminal vesicle invasion without lymph node involvement. Lymph node metastasis was found in 2.2%. The predictive effectiveness of the Partin table was high with an area under ROC curve of 0.733 for organ confinement, 0.738 for seminal vesicle invasion and 0.780 for lymph node involvement (CI 95%). CONCLUSION Our study demonstrated that the predictive ability of Partin tables for prostate cancer is also applicable to a Welsh population.
Collapse
Affiliation(s)
- Rajinikanth Ayyathurai
- Department of Urology, Glan Clwyd Hospital, Conwy and Denbighshire NHS Trust, Rhyl, Denbighshire, UK.
| | | | | | | | | | | |
Collapse
|
36
|
Karakiewicz PI, Eastham JA, Graefen M, Cagiannos I, Stricker PD, Klein E, Cangiano T, Schröder FH, Scardino PT, Kattan MW. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology 2006; 66:1245-50. [PMID: 16360451 DOI: 10.1016/j.urology.2005.06.108] [Citation(s) in RCA: 215] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2004] [Revised: 05/26/2005] [Accepted: 06/22/2005] [Indexed: 12/14/2022]
Abstract
OBJECTIVES To assess the prognostic significance of a positive surgical margin in the radical prostatectomy specimen, and to test for the presence of statistically significant interactions between surgical margin status and select pathologic stage variables. METHODS We combined prospectively collected data from 7816 consecutive patients treated with radical prostatectomy at eight institutions. The pretreatment serum prostate-specific antigen level, pathologic Gleason sum, surgical margin status (positive versus negative), presence of extracapsular extension, seminal vesicle involvement, and pelvic lymph node status were examined as predictors of the rate of biochemical progression in 5831 patients with complete records. RESULTS In multivariate Cox regression models, a positive surgical margin was associated with a 3.7-fold greater risk of progression (P = 0.001). Moreover, a statistically significant interaction was found between surgical margin status and Gleason sum 7 to 10 (P = 0.008) and lymph node invasion (P < 0.001). CONCLUSIONS The presence of a positive surgical margin in the radical prostatectomy specimen has an adverse effect on prognosis. The greatest risk of biochemical recurrence may be expected if a positive surgical margin is present with Gleason sum 7 to 10 disease or lymph node invasion.
Collapse
Affiliation(s)
- Pierre I Karakiewicz
- Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Greene KL, Elkin EP, Karapetian A, Duchane J, Carroll PR, Kane CJ. Prostate Biopsy Tumor Extent but Not Location Predicts Recurrence After Radical Prostatectomy: Results From CaPSURE. J Urol 2006; 175:125-9; discussion 129. [PMID: 16406887 DOI: 10.1016/s0022-5347(05)00056-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2005] [Revised: 07/28/2005] [Indexed: 11/26/2022]
Abstract
PURPOSE Prostate cancer biopsy information is important for patient risk assessment. Although the number and extent of positive biopsies have been used to predict recurrence, the impact of positive biopsy location and contiguity is less clear. We compared the ability of positive prostate biopsy location and pattern with number and percent positive biopsies to predict recurrence after RP. MATERIALS AND METHODS From CaPSURE we identified 2,037 men treated with RP from 1992 to 2002 for whom detailed biopsy information and 2 or more followup PSA values were available. Treatment failure was defined as 2 consecutive PSA values of 0.2 ng/ml or higher, or a second treatment delivered more than 6 months after RP. Biopsy tumor volume (number and percent positive sites), location of disease (anatomical site, laterality), and contiguity of positive biopsies were entered into Cox proportional hazards models to predict risk of disease recurrence while controlling for Gleason grade, PSA and T stage. RESULTS Higher number and percent of positive biopsy cores were associated with prostate cancer recurrence, risk stratification category and Gleason grade, p <0.0001, HR 1.09 (CI 1.02 to 1.16) and 1.01 (CI 1.00 to 1.01), respectively. Number of biopsy cores taken, laterality, contiguity and positive biopsy location were not associated with disease recurrence. CONCLUSIONS The number and the percentage of biopsies positive for cancer correlated with treatment failure after radical prostatectomy. Contiguity, laterality and location were not associated with recurrence.
Collapse
Affiliation(s)
- Kirsten L Greene
- Department of Urology, University of California, San Francisco Comprehensive Cancer Center, University of California, San Francisco, USA
| | | | | | | | | | | |
Collapse
|
38
|
Bracarda S, de Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, de Braud F, Bartsch G. Cancer of the prostate. Crit Rev Oncol Hematol 2005; 56:379-96. [PMID: 16310371 DOI: 10.1016/j.critrevonc.2005.03.010] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2005] [Accepted: 03/16/2005] [Indexed: 11/24/2022] Open
Abstract
Prostate carcinoma, with about 190,000 new cases occurring each year (15% of all cancers in men), is the most frequent cancer among men in northern and western Europe. Causes of the disease are essentially unknown, although hormonal factors are involved, and diet may exert an indirect influence; some genes, potentially involved in hereditary prostate cancer (HPC) have been identified. A suspect of prostate cancer may derive from elevated serum prostate-specific antigen (PSA) values and/or a suspicious digital rectal examination (DRE) finding. For a definitive diagnosis, however, a positive prostate biopsy is requested. Treatment strategy is defined according to initial PSA stage, and grade of the disease and age and general conditions of the patient. In localized disease, watchful waiting is indicated as primary option in patients with well or moderately differentiated tumours and a life expectancy <10 years, while radical prostatectomy and radiotherapy (with or without hormone-therapy) could be appropriate choices in the remaining cases. Hormone-therapy is the treatment of choice, combined with radiotherapy, for locally advanced or bulky disease and is effective, but not curative, in 80-85% of the cases of advanced disease. Patients who develop a hormone-refractory prostate cancer disease (HRPC) have to be evaluated for chemotherapy because of the recent demonstration of improved overall survival (2-2.5 months) and quality of life with docetaxel in more than 1,600 cases.
Collapse
|
39
|
Eskicorapci SY, Karabulut E, Türkeri L, Baltaci S, Cal C, Toktas G, Akpinar H, Ozer G, Sozen S, Tokuc R, Lekili M, Soylu A, Albayrak S, Sahin H, Alpar R, Ozen H. Validation of 2001 Partin tables in Turkey: a multicenter study. Eur Urol 2005; 47:185-9. [PMID: 15661412 DOI: 10.1016/j.eururo.2004.08.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/03/2004] [Indexed: 10/26/2022]
Abstract
OBJECTIVE Although Partin tables were developed in United States to predict the stage of prostate cancer preoperatively, they are used by many clinics throughout the world assuming that these figures apply to their population as well. However the predictive value of current Partin tables, which was updated in 2001, has not been validated in most of the countries as well as in Turkey. Therefore, we evaluated the validity of 2001 Partin tables, for the ability to predict the pathological stage in Turkish patients. PATIENTS AND METHODS The clinical and pathological findings of 1043 patients who have had radical prostatectomy were assessed. Serum PSA values, clinical stage, biopsy Gleason score and the pathological features of the radical prostatectomy specimens were collected from each clinic and evaluated. The predictive value of Partin nomogram and pathological findings of prostatectomy specimens were compared and analyzed according to Receiver Operating Characteristics (ROC) analysis. RESULTS Median age of the patients was 60 (45-74). In the presented study, percentage of patients with clinical stage T1c was 43%. Patients with Gleason score of 2-4 in biopsy constituted 23.4% of the study group. In the present study, the ratio of the patients with serum PSA higher than 10 ng/ml was 39.6%. Organ confined disease, seminal vesicle involvement, lymph node metastases ratios were 64.7%, 10.3%, 1.8% respectively. Area Under Curve (AUC) values for organ confined disease, seminal vesicle involvement and lymph node involvement were calculated as 0.665, 0.733 and 0.759 respectively. CONCLUSION It appears that Partin tables have a reasonable predictive value for the final pathological features like organ confined disease, seminal vesicle and lymph node involvement in Turkish patients. This multicenter study showed that current Partin tables could also be used in Turkish patients with comparable accuracy.
Collapse
|
40
|
Graefen M, Michl UH, Heinzer H, Friedrich MG, Eichelberg C, Haese A, Huland H. Indication, Technique and Outcome of Retropubic Nerve-Sparing Radical Prostatectomy. ACTA ACUST UNITED AC 2005. [DOI: 10.1016/j.euus.2005.03.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
41
|
Steuber T, Karakiewicz PI, Augustin H, Erbersdobler A, Lange I, Haese A, Chun KHF, Walz J, Graefen M, Huland H. Transition zone cancers undermine the predictive accuracy of Partin table stage predictions. J Urol 2005; 173:737-41. [PMID: 15711259 DOI: 10.1097/01.ju.0000152591.33259.f9] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE The Partin tables represent the most widely used predictor of pathological stage in men with localized prostate cancer (PCa). The accuracy and performance of the tables have been tested across different populations. However, to our knowledge the potential limitations that may stem from differences between transition zone (TZ) and peripheral zone (PZ) prostate cancers has not been explored. We tested the predictive accuracy and performance of the Partin tables according to TZ vs PZ tumor predominance. MATERIALS AND METHODS Preoperative serum prostate specific antigen, clinical stage and biopsy Gleason sum data on 1,990 patients treated with radical retropubic prostatectomy were used to define the 2001 Partin probabilities of organ confinement and seminal vesicle invasion (SVI). Data on 1,320 patients who underwent staging pelvic lymphadenectomy and radical retropubic prostatectomy were used to define the probabilities of lymph node invasion (LNI) and organ confined disease (OC). ROC area under the curve was used to assess the predictive accuracy of the 2001 Partin tables relative to observed extracapsular extension (ECE), SVI, LNI and OC. Performance characteristics for each prediction were explored graphically with local regression, nonparametric smoothing plots. Results were compared between 222 TZ cancers and 1,768 PZ cancers. RESULTS The 1,990 radical retropubic prostatectomy specimens demonstrated ECE in 689 cases (34.6%) (TZ in 58 or 27.1% and PZ in 631 or 35.8%) and SVI in 224 (TZ in 13 or 6.1% and PZ in 211 or 11.9%). The 1,320 lymphadenectomy specimens demonstrated LNI in 56 cases (TZ in 2 or 0.9% and PZ in 54 or 4.6%). OC was found in 784 cases (59.4%) (TZ in 95 or 69.9% and PZ in 689 or 58.2%). Predictive accuracy was for ECE 76.4% (TZ 69.0% and PZ 77.2%), 78.0% for SVI (TZ 73.5% and PZ 78.3%), 78.6% for LNI (TZ 44.5% and PZ 79.9%) and 79.4% for OC (TZ 73.8% and PZ 80.0%). CONCLUSIONS The biological tumor characteristics of TZ PCa differ from those of PZ PCa. These differences appear to undermine the accuracy of pathological stage predictions.
Collapse
Affiliation(s)
- T Steuber
- Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Luebke AM, Schlomm T, Gunawan B, Bonkhoff H, Füzesi L, Erbersdobler A. Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach. Virchows Arch 2005; 446:338-41. [PMID: 15726402 DOI: 10.1007/s00428-004-1199-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2004] [Accepted: 12/06/2004] [Indexed: 11/25/2022]
Abstract
Basal cell tumours of the prostatic gland are rare, and the classification is difficult. In the present case report, a large, tumour-like proliferation of atypical basaloid cells was found incidentally in a prostatectomy specimen that otherwise contained a conventional acinar adenocarcinoma. The basaloid cells displayed a solid or adenoid-cystic growth pattern and strongly expressed high-molecular-weight cytokeratins and bcl-2. A high Ki-67 index was recorded within the atypical basaloid cells, by far exceeding the one counted in the conventional adenocarcinoma. However, there were no definite criteria for a malignant behaviour of the basal cell tumour. Comparative genomic hybridisation from microdissected tumour cells yielded losses at the short arms of chromosomes 8 and 12 in the conventional adenocarcinoma and a normal karyotype in the basal cell tumour. The pathological findings favoured the diagnosis of an atypical basal cell hyperplasia.
Collapse
Affiliation(s)
- A M Luebke
- Department of Urology, University of Hamburg, Martinistrasse 52, 22081 Hamburg, Germany
| | | | | | | | | | | |
Collapse
|
43
|
Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TLJ, Tasdemir I, Morris T, Carroll K. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2005; 172:1871-6. [PMID: 15540741 DOI: 10.1097/01.ju.0000139719.99825.54] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE We evaluated the benefits of adding 150 mg bicalutamide to standard care, that is radical prostatectomy, radiotherapy or watchful waiting (WW), in patients with localized or locally advanced prostate cancer. MATERIALS AND METHODS A total of 1,218 men with T1-4, M0, any N prostate cancer were recruited from 62 Scandinavian centers and randomized 1:1 to 150 mg bicalutamide or placebo plus standard care. Primary end points were progression-free survival (PFS) and overall survival. RESULTS At a median 5.3-year followup patients with locally advanced disease had improved survival with bicalutamide (HR 0.68, 95% CI 0.50 to 0.92), while those with localized disease had decreased survival with bicalutamide (HR 1.47, 95% CI 1.06 to 2.03). Bicalutamide significantly improved PFS, decreasing the risk of disease progression by 43% compared with placebo (HR 0.57, 95% CI 0.48 to 0.68, p<0.0001). The rate of events was 35.4% for bicalutamide and 46.2% for placebo. Patients with locally advanced disease gained the greatest PFS benefits with bicalutamide (HR 0.40, 95% CI 0.31 to 0.52). Since 81% of the trial population were untreated before entry and would otherwise have undergone WW, the findings essentially reflect the results of immediate hormone therapy vs WW. CONCLUSIONS Bicalutamide (150 mg) provides significant benefit in patients with locally advanced disease. In previously untreated patients there may be a tumor burden below which endocrine therapy provides no benefit or may even decrease survival.
Collapse
Affiliation(s)
- Peter Iversen
- Department of Urology, University of Copenhagen, Rigshospitalet and Herlev Hospital, Copenhagen, Denmark.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Delaney G, Jacob S, Barton M. Estimating the optimal external-beam radiotherapy utilization rate for genitourinary malignancies. Cancer 2005; 103:462-73. [PMID: 15612081 DOI: 10.1002/cncr.20789] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Benchmark radiotherapy utilization rates for genitourinary malignancies are largely unknown, despite the finding that genitourinary cancers comprise approximately 19% of all registered malignancies in Australia. METHODS To develop an evidence-based benchmark of the optimal proportion of patients with genitourinary malignancies who should receive at least one course of radiotherapy at some time during their illness, the authors studied treatment guidelines and treatment reviews regarding genitourinary malignancies. Optimal radiotherapy utilization trees were constructed to show the clinical attributes that indicated possible benefit from radiotherapy based on evidence. Epidemiologic incidence data for each of these clinical attributes were obtained to calculate the optimal proportion of all patients with genitourinary cancer for whom radiotherapy was considered appropriate. RESULTS The proportion of patients with genitourinary malignancies for whom radiotherapy was indicated at some point in their illness, according to the best available evidence, was estimated to be 27% of patients with renal cancer, 58% of patients with bladder cancer, 60% of patients with prostate cancer, and 49% of patients with testicular cancer. The occurrence of ureteric and penile cancers among patients was too rare, and, therefore, these patients were not included in the current study. CONCLUSIONS There was a large discrepancy between actual radiotherapy utilization and the evidence-based optimal rate. The authors recommended strategies to implement the evidence-based guidelines. Evidence-based benchmarks for radiotherapy utilization rates such as the ones described in the current study were important in the evaluation of the appropriate use of radiotherapy.
Collapse
Affiliation(s)
- Geoff Delaney
- Collaboration for Cancer Outcomes Research and Evaluation, Liverpool Hospital, Sydney, Australia.
| | | | | |
Collapse
|
45
|
Abstract
BACKGROUND Radical prostatectomy and radiotherapy (RT), both radical therapies, are the standard treatments of curative intent for early prostate cancer. However, these therapies are not curative in all patients and, consequently, a substantial proportion of treated patients remain at risk of disease progression and/or cancer-related death. METHODS This article presents contemporary data on the incidence of prostate-specific antigen (PSA) and clinical disease progression after primary therapy of curative intent in relation to commonly assessed pretreatment or pathologic disease characteristics. RESULTS The data highlight the substantial risk of progression for certain patient groups, such as those with Gleason score 8-10, cT3 disease, lymph node metastases, and/or pretreatment PSA levels > 20 ng/mL. CONCLUSIONS Improved and/or additional treatment options are needed for these patient groups.
Collapse
Affiliation(s)
- Mark Soloway
- Department of Urology, University of Miami School of Medicine, Miami, Florida 33136, USA.
| | | |
Collapse
|
46
|
Greene KL, Meng MV, Elkin EP, Cooperberg MR, Pasta DJ, Kattan MW, Wallace K, Carroll PR. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure). J Urol 2004; 171:2255-9. [PMID: 15126797 DOI: 10.1097/01.ju.0000127733.01845.57] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE The Kattan preoperative nomogram combines preoperative prostate specific antigen (PSA), biopsy Gleason grade and clinical stage to estimate disease recurrence after radical prostatectomy. Several studies using patient data from academic centers have validated the nomogram. We assessed the performance of the Kattan nomogram using the Cancer of the Prostate Strategic Urological Research Endeavor database, a national, largely community based observational disease registry. MATERIALS AND METHODS From the Cancer of the Prostate Strategic Urological Research Endeavor database we identified 1701 men with clinically localized prostate cancer undergoing radical prostatectomy with sufficient pretreatment information and PSA followup after surgery. Disease recurrence was defined as 2 consecutive PSA values 0.2 ng/ml or greater, or a second cancer treatment more than 6 months after prostatectomy. A concordance index was used to evaluate the performance of the nomogram compared to observed 5-year recurrence-free survival (Kaplan-Meier). Kattan nomogram scores were calculated for each patient and stratified into 6 groups for analysis. RESULTS In our cohort of 1701 men 413 (24%) had evidence of disease recurrence. Median followup in these patients was 2.3 years. Kattan nomogram scores were 17% to 99% (mean 79%). The overall concordance index was 0.68. Varying the definition of recurrent disease and excluding patients with imputed data did not substantially alter nomogram performance (concordance index 0.65 to 0.70). The Kattan nomogram tended to overestimate 5-year freedom from recurrence in patients with scores of 65% and higher. CONCLUSIONS We noted the reasonable performance of the Kattan nomogram for predicting cancer outcomes after radical prostatectomy using a community based population. Although concordance is lower than in previous validation studies and the nomogram overestimates recurrence-free survival in patients at lower risk, the model is fairly robust and it provides important information when counseling patients regarding treatment options in the community setting. Further refinements in pretreatment estimation of disease-free survival and ultimately overall survival are needed.
Collapse
Affiliation(s)
- Kirsten L Greene
- Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California-San Francisco 94115-1711, USA
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113:913-23. [PMID: 15067324 PMCID: PMC362118 DOI: 10.1172/jci20032] [Citation(s) in RCA: 360] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2003] [Accepted: 12/16/2003] [Indexed: 01/28/2023] Open
Abstract
One of the major problems in management of prostate cancer is the lack of reliable genetic markers predicting the clinical course of the disease. We analyzed expression profiles of 12,625 transcripts in prostate tumors from patients with distinct clinical outcomes after therapy as well as metastatic human prostate cancer xenografts in nude mice. We identified small clusters of genes discriminating recurrent versus nonrecurrent disease with 90% and 75% accuracy in two independent cohorts of patients. We examined one group of samples (21 tumors) to discover the recurrence predictor genes and then validated the predictive power of these genes in a different set (79 tumors). Kaplan-Meier analysis demonstrated that recurrence predictor signatures are highly informative (P < 0.0001) in stratification of patients into subgroups with distinct relapse-free survival after therapy. A gene expression-based recurrence predictor algorithm was informative in predicting the outcome in patients with early-stage disease, with either high or low preoperative prostate-specific antigen levels and provided additional value to the outcome prediction based on Gleason sum or multiparameter nomogram. Overall, 88% of patients with recurrence of prostate cancer within 1 year after therapy were correctly classified into the poor-prognosis group. The identified algorithm provides additional predictive value over conventional markers of outcome and appears suitable for stratification of prostate cancer patients at the time of diagnosis into subgroups with distinct survival probability after therapy.
Collapse
|
48
|
Pepe P, Panella P, Motta L, Savoca F, D'Arrigo L, Candiano G, Pennisi M, Aragona F. Preoperative Prediction of Pathological Stage by Quantitative Histology in 102 Patients with Prostate Cancer (PCa) and Serum PSA ≤10 ng/mL. Urologia 2004. [DOI: 10.1177/039156030407100205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Purpose. To find a predictor of extraprostatic extension in clinically localized prostate cancer (PCa), preoperative ultrasound-guided prostate needle biopsies and clinicopathological data were reviewed. Materials and Methods 102 consecutive patients (median age 63 years) with serum PSA ≤10 ng/mL who underwent radical retropubic prostatectomy were included. Preoperative prostate biopsies according to an extended protocol were performed and whole-mount prostatectomy specimens were processed. One or more of the following biopsy variables were considered predictive of locally andvanced PCa: more than 2/12 cancer-positive cores, total percentage of cancer (TPC) >20%, greatest percentage of cancer (GPC) >50%, bilateral PCa, presence of cancer in both lateral portions, Gleason score >6. Results Only 32/102 (31.4%) specimens showed an organ-confined PCa; the remaining were pT3a in 30 (29.4%) cases, pT3b in 6 (5.9%) and pT2–T3 with positive surgical margins in 34 (33.3%). Quantitative histology predicted an organ-confined PCa in 41.2% of patients. In all 102 patients and in 56 with T1c clinical stage, the positive predictive value (PPV) and negative predictive value (NPV) of biopsy findings, to predict an organ confined PCa, was 81.2 vs 92% and 91.6 vs 93.4%, respectively. The PPV and NPV to predict a locally advanced PCa was 92.8 and 86.5%, respectively. Conclusions Quantitative histology seems to be helpful for locally staging of PCa in patients with T1c clinical stage and PSA ≤10 ng/mL.
Collapse
Affiliation(s)
- P. Pepe
- Unità Operativa di Urologia, Azienda Ospedaliera “Cannizzaro”, Catania
| | - P. Panella
- Unità Operativa di Urologia, Azienda Ospedaliera “Cannizzaro”, Catania
| | - L. Motta
- Unità Operativa di Urologia, Azienda Ospedaliera “Cannizzaro”, Catania
| | - F. Savoca
- Unità Operativa di Urologia, Azienda Ospedaliera “Cannizzaro”, Catania
| | - L. D'Arrigo
- Unità Operativa di Urologia, Azienda Ospedaliera “Cannizzaro”, Catania
| | - G. Candiano
- Unità Operativa di Urologia, Azienda Ospedaliera “Cannizzaro”, Catania
| | - M. Pennisi
- Unità Operativa di Urologia, Azienda Ospedaliera “Cannizzaro”, Catania
| | - F. Aragona
- Unità Operativa di Urologia, Azienda Ospedaliera “Cannizzaro”, Catania
| |
Collapse
|
49
|
Graefen M, Ohori M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Erbersdobler A, Henke RP, Huland H, Wheeler TM, Slawin K, Scardino PT, Kattan MW. Assessment of the Enhancement in Predictive Accuracy Provided by Systematic Biopsy in Predicting Outcome for Clinically Localized Prostate Cancer. J Urol 2004; 171:200-3. [PMID: 14665876 DOI: 10.1097/01.ju.0000099161.70713.c8] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE Current localized prostate cancer treatment outcome nomograms rely on prostate specific antigen (PSA), tumor stage and grade. We investigated whether the addition of prostate biopsy features may enhance the accuracy of a nomogram predicting recurrence after radical prostatectomy (RP). MATERIALS AND METHODS Clinical data from 1,152 patients who underwent RP were used and included PSA, clinical stage, biopsy Gleason grade and systematic biopsy information that quantified the amount of cancer and high grade cancer. Predictive accuracy for freedom from recurrence after RP was assessed with and without tumor quantification in the biopsy by the area under the receiver operating characteristics curve (AUC). RESULTS Percentage and number of cores with cancer, and percentage and number of cores with high grade cancer were predictors of outcome when added to models that included PSA, Gleason grade and clinical stage (all p <0.0001). Nomogram accuracy with 3 traditional variables (AUC 0.790) was minimally enhanced with the addition of percentage or number of positive cores (AUC 0.804 and 0.800, respectively), or percentage or number of cores with high grade cancer (AUC 0.802 and 0.800, respectively). Maximum predictive accuracy of 0.811 was achieved after supplementing the traditional 3-variable nomogram with various combinations of additional pathological predictors. CONCLUSIONS The information provided by systematic biopsies substantially improves the ability to predict outcome following RP. However, some incremental predictive accuracy was achieved by adding systematic biopsy features.
Collapse
Affiliation(s)
- Markus Graefen
- Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Rydh A, Lundblad M, Ahlström KR, Tavelin B, Stattin P. MRI of the skeleton in prostate cancer staging. SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY 2003; 37:222-5. [PMID: 12775281 DOI: 10.1080/00365590310008091] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
OBJECTIVE To explore the value of MRI in the detection of bone metastases in newly diagnosed prostate cancer. MATERIAL AND METHODS MRI examinations of the axial skeleton in 76 patients with newly diagnosed prostate cancer were reviewed, and the relation of these findings to the serum level of prostate specific antigen (PSA) was examined. RESULTS MRI indicated bone metastases in 26/76 patients (34%) in the entire study group, in 4/24 (17%) with serum PSA <20 ng/ml and in 22/52 (42%) with serum PSA >20 ng/ml. CONCLUSIONS These results suggest that MRI is a more sensitive indicator of suspected bone metastases than bone scintigraphy in the low range of serum PSA, but less sensitive in the high range. Further studies of MRI and bone scintigraphy in parallel in patients with serum PSA <20 ng/ml are needed to elucidate their relative value in the staging of patients with prostate cancer.
Collapse
Affiliation(s)
- Anders Rydh
- Department of Diagnostic Radiology, Umeå University, Sweden.
| | | | | | | | | |
Collapse
|